Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
  • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
  • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
  • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5089—Processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the invention relates to a method for producing encased, containing spherical granules Prostane derivatives.
• Prostan derivatives and their preparation are described in detail in EP 0 011 591 (filing date: 18.10.1979).
• the prostane derivatives are compounds derived from prostacyclin (PGI 2 ). They contain a methylene group in place of the 9 - ether oxygen atom in prostacyclin. Prostan derivatives are used to treat a variety of diseases, with a focus on cardiovascular and thromboaggregation inhibiting effects.
• the use of prostane derivatives as a medicament is described in detail in European publication EP 0 011 591.
• the publications EP 0 055 208, EP 0 099 538 and EP 0 119 949 list carbacyclin derivatives which have similar indications to the previously mentioned prostane derivatives.
• Other prostane derivatives are described in publication EP 0 084 856, which have been suggested for use in inhibiting platelet aggregation, lowering systemic blood pressure or treating gastric ulcers. Iloprost is the most important prostane derivative.
• polymers As coating materials for oral sustained release dosage forms polymers have a gained outstanding importance.
• the types of polymer used are it is primarily ethyl cellulose or poly (meth) acrylic acid ester.
• the Polymers can be either as an organic solution or in an aqueous phase be applied dispersed. Because they are environmentally friendly, safer and cheaper, are becoming increasingly watery in the industry Polymer dispersions used.
• the most famous trade names are Aquacoat ECD 30®, Surelease® or Eudragit® NE 30 D, RL 30 D and RS 30 D.
• In the paint suspensions used for the coating process are contain additional additives that are production- and application-related are required and determine the properties of the film former.
• the wrapping process of pellets takes place with a Polymer membrane in fluidized bed equipment.
• a flow of air arrange themselves the pellets to a fluidized or fluidized bed, depending on the type of device in the Counterflow or pouring current (top or bottom spraying) from one Spraying (one or more spray nozzles) with the polymer dispersion the added additives is sprayed.
• the movement in the Fluidized bed distributes the finely divided dispersion on the surface of the Pellets.
• the dispersant evaporates water through the water Drying current of the air, and the latex particles are approaching to one always becoming denser globular packing.
• Coalescence is called.
• the film now surrounding the pellet acts as a diffusion barrier for the drug in the nucleus and leads to it a delayed drug release.
• active ingredient-containing raw pellets are Extrusion / Sppurronisationsprozeß made.
• the raw pellets persist 90% of lactose and 10% Avicel PH 101 as auxiliaries and contain as Active substance iloprost- ⁇ -cyclodextrin clathrate.
• the content is 0.05 or 0.1 mg Iloprost per 65 or 130 mg pellets [active substance content approx. 0.08% (w / w)]
• the raw pellets are then treated with a coating suspension, based on Eudragit NE 30 D and additives in a fluidized bed apparatus coated.
• the first larger batches were in the WSG Aeromatic MP4 (Aeromatic) coated. Just like in the smaller ones Laboratory equipment was the spray order in the countercurrent process (Top-Spraying) instead of. It was from a spray nozzle from the top in opposite Direction to the supply air flow to the pellets located in the fluidized bed sprayed.
• the spray order in the countercurrent process Topic-Spraying
• 75 kg each contained active ingredients Raw pellets sprayed with 16.5 kg of lacquer suspension.
• the polymer dispersant either ethylcellulose or a Poly (meth) acrylic ester as a polymer comprises.
• the thickness of the applied polymer evenly over the pellet is distributed. So should the tolerances of the polymer thickness advantageously only ⁇ 30%, preferably ⁇ 20% and more preferably ⁇ 10%.
• a tablet or a slow release capsule which are, for example, hard gelatin capsules.
• the filling in capsules is preferred.
• other bottlings or containers of encased Pellets are possible. Such containers may be present in IUDs there releasing a steroid retarded.
• the bottlings can be used as tablets be used with easily releasable molding compound.
• the pellets as active ingredient Prostane derivatives and pharmaceutical carriers and / or additives.
• the active ingredient is 5- (E) - (1 S, 5S, 6R) -7-hydroxy-6 [(E) - (3S, 4RS) -3-hydroxy-4-methyl-1-octen-6-inyl] bicyclo [3.3.0] octen-3-ylidene pentanoic acid and as an additive at least cyclodextrin
• the inventive Temperungs claim developed.
• the annealing at 50 ° C for 48 h is suitable for releasing the drug in the present formulation to stabilize reproducibly and to keep constant over the storage time.
• Ethyl cellulose is described in Römpp Chemie Lexikon, 9th edition, 1990, Ed. J. FALBE and M. REGITZ, Georg Thieme Verlag, Stuttgart (ISBN 3-13-734709-2) on page 1254.
• the pellets comprise, as crude pellets, the active pharmaceutical ingredient and also pharmaceutically acceptable carriers and additives.
• Such carriers and additives are described in Remington's Pharmaceutical Science, 15 th ed. Mack Publishing Company, Easton Pennsylvania (1980).
• Cyclodextrin is released after degradation of starch by Bacillus macerans or Bacillus circulans under action formed by cyclodextrin glycosyltransferase.
• the cyclodextrins consist of 6, 7 or 8 ⁇ -1-4 linked glucose units ( ⁇ -, ⁇ - and ⁇ -cyclodextrins).
• the Cyclohexa- (hepta-, octa-) amyloses are present in the crystal lattice of the cyclodextrins stacked together to form continuous innermolecular channels, in which they include hydrophobic molecules in varying amounts can.
• EP 0 011 591, EP 0 055 208, EP 0 099 538, EP 0 119 949, EP 0 084 856 and EP 0 686 036 describe the prostane derivatives whose Manufacture and use.
• Salt formation with the free acids are inorganic and organic bases suitable, as those skilled in the formation of physiologically acceptable salts are known.
• examples include: alkali metal hydroxides, such as sodium and Potassium hydroxide, alkaline earth hydroxides, such as calcium hydroxide, ammonia, amines, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, Tris- (hydroxymethyl) -methylamine, etc.
• alkali metal hydroxides such as sodium and Potassium hydroxide
• alkaline earth hydroxides such as calcium hydroxide
• ammonia amines, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, Tris- (hydroxymethyl) -methylamine, etc.
• the ⁇ -cyclodextrin clathrates become produced according to EP 0 259 468.
• prostane derivative with the Name "Iloprost” and which is the systematic name 5- (E) - (1 S, 5S, 6R) -7-hydroxy-6 [(E) - (3S, 4RS) -3-hydroxy-4-methyl-1-octen-6-inyl] bicyclo [3.3.0] octen-3-ylidene carries pentanoic acid.
• the active substances include the substances cicaprost, eptaloprost, Ciprosten and / or beraprost and their salts.
• compositions can also be used as low-dose agents are present, these are active substance contents of 1% and less (w / w) based on the total mass of active ingredient and carrier and additive. Preferred is a percentage of 0.3 and less; more preferably from 0.1 and fewer.
• a thickness of the polymer is from 1.5 to 4% (w / w) of the total mass, more preferably a thickness of 1.75 to 3%, and most preferably one Thickness of 2.1% ⁇ 10% (2.0 - 2.2%).
• the lower temperature limit is 45 ° C, more preferably 47 ° C, even more preferably 48 ° C, and most preferably 50 ° C.
• the upper temperature limit is 65 ° C, more preferably 60 ° C, even more preferably 47 ° C, and most preferably 53 ° C.
• the residence time for annealing is at least 24 hours. Comparable good results are achieved by prolonged tempering. worse Data for the drug release profile can be shortened to reach. Usually, a high temperature can increase the stability of the Affect the product. Therefore are as short as possible and gentle Conditions for annealing desirable. Most preferred is one Residence time of 48 h ⁇ 5h.
• Example 1 old method, top spraying, production scale, no tempering
• the sustained-release pellets thus obtained have the following composition: 0.050 mg iloprost 0.330 mg ⁇ -cyclodextrin 56.260 mg Lactose, 90% ⁇ 0.1 mm 6.250 mg Avicel PH 101 1.777 mg Eudragit® NE 0.075 mg magnesium stearate 0.055 mg Titanium dioxide 0.034 mg Polyethylene glycol 6000 0.039 mg Polysorbate 80 0.134 mg silica 65.00 mg release pellets
• Example 2 (old method, top spraying, laboratory scale, untempered and annealed at 50 ° C / 4 hours)
• the sustained-release pellets thus obtained have the following composition: 0.050 mg iloprost 0.330 mg ⁇ -cyclodextrin 54.632 mg Lactose, 90% ⁇ 0.1 mm 6.113 mg Avicel PH 101 2,549 mg Eudragit® NE 0.110 mg magnesium stearate 0.979 mg Titanium dioxide 0.048 mg Polyethylene glycol 6000 0.057 mg Polysorbate 80 0.132 mg silica 65,000 mg release pellets
• Example 3 (modified, new process, bottom spraying, production scale, annealing at 50 ° C / 4 hours)
• the sustained-release pellets thus obtained have the following composition: 0.050 mg iloprost 0.330 mg ⁇ -cyclodextrin 56.606 mg Lactose, 90% ⁇ 0.1 mm 6.332 mg Avicel PH 101 1.392 mg Eudragit® NE 0.059 mg magnesium stearate 0.044 mg Titanium dioxide 0.027 mg Polyethylene glycol 6000 0.030 mg Polysorbate 80 0.130 mg silica 65,000 mg release pellets
• Example 3 Storage took place at room temperature. As in Example 3, this indicates 50 ° C for 4 h annealed product a decrease in the release rates a storage period of 4 weeks. The product is also not stable.
• Example 4 ( new process / final process, bottom spraying, production scale, unannealed and annealing at 50 ° C / 48 hours)
• the sustained release pellets at 50 ° C in Circulating air drying oven annealed for 48 hours.
• the sustained-release pellets thus obtained have the following composition: 0.050 mg iloprost 0.330 mg ⁇ -cyclodextrin 56.628 mg Lactose, 90% ⁇ 0.1 mm 6.334 mg Avicel PH 101 1.374 mg Eudragit® NE 0.058 mg magnesium stearate 0.042 mg Titanium dioxide 0.025 mg Polyethylene glycol 6000 0.030 mg Polysorbate 80 0.129 mg silica 65,000 mg release pellets

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Toxicology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Glanulating (AREA)
• Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
• Processes Of Treating Macromolecular Substances (AREA)
• Jellies, Jams, And Syrups (AREA)
• Manufacturing Of Micro-Capsules (AREA)
• Steroid Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=7859315

Family Applications (1)

Country Status (18)

Families Citing this family (7)

Family Cites Families (11)

• 1998
  • 1998-02-24 DE DE19808634A patent/DE19808634A1/de not_active Ceased
• 1999
  • 1999-02-24 WO PCT/EP1999/001100 patent/WO1999043303A1/de active IP Right Grant
  • 1999-02-24 SK SK1242-2000A patent/SK284062B6/sk not_active IP Right Cessation
  • 1999-02-24 CA CA002321969A patent/CA2321969C/en not_active Expired - Fee Related
  • 1999-02-24 PL PL342315A patent/PL193071B1/pl not_active IP Right Cessation
  • 1999-02-24 AT AT99908932T patent/ATE303133T1/de not_active IP Right Cessation
  • 1999-02-24 EP EP99908932A patent/EP1058542B1/de not_active Expired - Lifetime
  • 1999-02-24 RU RU2000124537/14A patent/RU2209060C2/ru not_active IP Right Cessation
  • 1999-02-24 DK DK99908932T patent/DK1058542T3/da active
  • 1999-02-24 CZ CZ20003088A patent/CZ299252B6/cs not_active IP Right Cessation
  • 1999-02-24 AU AU28352/99A patent/AU753261B2/en not_active Ceased
  • 1999-02-24 KR KR1020007009291A patent/KR100623542B1/ko not_active IP Right Cessation
  • 1999-02-24 DE DE59912501T patent/DE59912501D1/de not_active Expired - Lifetime
  • 1999-02-24 HU HU0100752A patent/HU226066B1/hu not_active IP Right Cessation
  • 1999-02-24 ES ES99908932T patent/ES2247786T3/es not_active Expired - Lifetime
  • 1999-02-24 JP JP2000533102A patent/JP2002504506A/ja active Pending
  • 1999-02-24 US US09/622,811 patent/US6723372B1/en not_active Expired - Fee Related
  • 1999-02-24 IL IL13796599A patent/IL137965A/xx not_active IP Right Cessation
• 2000
  • 2000-08-23 NO NO20004225A patent/NO20004225L/no not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events